J.P. Morgan Healthcare Conference
Refine Search
Biotechnology
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 JP Morgan Healthcare Conference, is set to transform the chronic obstructive pulmonary disease (COPD) treatment. 17 January 2025
Biotechnology
French pharma major Sanofi's participation at the JP Morgan Healthcare Conference was marked by a comprehensive overview of its position in 2024 and its strategic vision for the future. 16 January 2025
Pharmaceutical
Eli Lilly saw its shares close down 6.6% at $744.91 yesterday, after it revealed forecast for sales at the JP Morgan Healthcare Conference. 15 January 2025
Pharmaceutical
Belgian drugmaker UCB has presented what it calls its ‘growth journey’ and the strategic priorities driving future success at the 43rd JP Morgan (JPM) Healthcare Conference in San Francisco, USA. 15 January 2025
Biotechnology
German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA therapeutics, immunomodulators, and targeted therapies at the 43rd Annual JP Morgan Healthcare Conference in San Francisco, California. 14 January 2025
Biosimilars
South Korea’s Celltrion has announced the next phase of its strategic transformation from a developer of the world's first monoclonal antibody (MAb) biosimilar to an innovative company focused on new drug development at the 42nd Annual JP Morgan Healthcare Conference in San Francisco, California. 15 January 2024
Pharmaceutical
Earlier this month US biotech major Amgen presented at the JP Morgan’s 42nd Annual Healthcare Conference, highlighting its pillars of business. 15 January 2024
Biotechnology
Blueprint Medicines Corporation has outlined its 2024 corporate strategy, promising accelerated revenue growth, sustainable research and development, and a clear path to profitability. 9 January 2024
Biotechnology
UK pharma major GSK has entered into an agreement to acquire Anglo-American biotech Aiolos Bio, a clinical-stage company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions. 9 January 2024
Biotechnology
US pharma giant Merck & Co entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon Therapeutics for $23.00 per share. 9 January 2024
Biotechnology
Kicking of the JP Morgan Healthcare conference this morning, Johnson & Johnson announced a definitive agreement to acquire Ambrx Biopharma. 8 January 2024
Biotechnology
Mersana Therapeutics today announced business updates, its expected milestones and its upcoming presentation at the 42nd Annual JP Morgan Healthcare Conference. 5 January 2024
Biotechnology
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 JP Morgan Healthcare Conference, is set to transform the chronic obstructive pulmonary disease (COPD) treatment. 17 January 2025
Biotechnology
French pharma major Sanofi's participation at the JP Morgan Healthcare Conference was marked by a comprehensive overview of its position in 2024 and its strategic vision for the future. 16 January 2025
Pharmaceutical
Eli Lilly saw its shares close down 6.6% at $744.91 yesterday, after it revealed forecast for sales at the JP Morgan Healthcare Conference. 15 January 2025
Pharmaceutical
Belgian drugmaker UCB has presented what it calls its ‘growth journey’ and the strategic priorities driving future success at the 43rd JP Morgan (JPM) Healthcare Conference in San Francisco, USA. 15 January 2025
Biotechnology
German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA therapeutics, immunomodulators, and targeted therapies at the 43rd Annual JP Morgan Healthcare Conference in San Francisco, California. 14 January 2025
Biosimilars
South Korea’s Celltrion has announced the next phase of its strategic transformation from a developer of the world's first monoclonal antibody (MAb) biosimilar to an innovative company focused on new drug development at the 42nd Annual JP Morgan Healthcare Conference in San Francisco, California. 15 January 2024
Pharmaceutical
Earlier this month US biotech major Amgen presented at the JP Morgan’s 42nd Annual Healthcare Conference, highlighting its pillars of business. 15 January 2024
Biotechnology
Blueprint Medicines Corporation has outlined its 2024 corporate strategy, promising accelerated revenue growth, sustainable research and development, and a clear path to profitability. 9 January 2024
Biotechnology
UK pharma major GSK has entered into an agreement to acquire Anglo-American biotech Aiolos Bio, a clinical-stage company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions. 9 January 2024
Biotechnology
US pharma giant Merck & Co entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon Therapeutics for $23.00 per share. 9 January 2024
Biotechnology
Kicking of the JP Morgan Healthcare conference this morning, Johnson & Johnson announced a definitive agreement to acquire Ambrx Biopharma. 8 January 2024
Biotechnology
Mersana Therapeutics today announced business updates, its expected milestones and its upcoming presentation at the 42nd Annual JP Morgan Healthcare Conference. 5 January 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze